Major depressive disorder, often simply referred to as depression, is a mental disorder characterized by prolonged unhappiness or irritability. It is accompanied by a constellation of somatic and cognitive signs and symptoms such as fatigue, apathy, sleep problems, loss of appetite, loss of engagement, low self-regard/worthlessness, difficulty concentrating or indecisiveness, or recurrent thoughts of death or suicide.
Depression in childhood and adolescence is similar to adult major depressive disorder, although young sufferers may exhibit increased irritability or behavioral discontrol instead of the more common sad, empty, or hopeless feelings that are seen with adults. Children who are under stress, experiencing loss or grief, or have other underlying disorders are at a higher risk for depression. Childhood depression is often comorbid with mental disorders outside of other mood disorders, most commonly anxiety disorder and conduct disorder. Highlighting the pivotal role of adolescence and young adulthood, the National Alliance on Mental Illness reports that 75 percent of mental health disorders commence by age 24, emphasizing the urgency of addressing youth mental health challenges. Depression also tends to run in families. In a 2016 Cochrane review, cognitive behavior therapy (CBT), third-wave CBT and interpersonal therapy demonstrated small positive benefits in the prevention of depression. Psychologists have developed different treatments to assist children and adolescents suffering from depression, though the legitimacy of the diagnosis of childhood depression as a psychiatric disorder, as well as the efficacy of various methods of assessment and treatment, remains controversial.
Base rates and prevalence
About 8% of children and adolescents suffer from depression. In 2016, 51% of students (teens) who visited a counseling center reported having anxiety, followed by depression (41%), relationship concerns (34%) and suicidal ideation (20.5%). Many students reported experiencing multiple conditions at once. Research suggests that the prevalence of children with major depressive disorder in Western cultures ranges from 1.9% to 3.4% among primary school children. Among teenagers, up to 9% meet criteria for depression at a given moment and approximately 20% experience depression sometime during adolescence. Studies have also found that among children diagnosed with a depressive episode, there is a 70% rate of recurrence within five years. Furthermore, 50% of children with depression will have a recurrence at least once during their adulthood. While there is no gender difference in depression rates up in those under 15 after that age the rate among women doubles compared to men. However, in terms of recurrence rates and symptom severity, there is no gender difference. In an attempt to explain these findings, one theory asserts that preadolescent women on average have more risk factors for depression when compared to men. These risk factors then combine with the typical stresses and challenges of adolescent development to trigger the onset of depression. Depression in youth and adolescence is associated with a wide array of outcomes that can come later in life for the affected individual. Some of these outcomes include poor physical and mental health, trouble functioning socially, and suicide.
Suicidal intent
Like their adult counterparts, children and adolescents suffering from depression are at an increased risk of attempting or committing suicide. Suicide is the fourth leading cause of death among 15- to 19-year-olds. Adolescent males may be at an even higher risk of suicidal behavior when also presenting with a conduct disorder. In the 1990s, the National Institute of Mental Health (NIMH) found that up to 7% of adolescents who develop major depressive disorder may commit suicide as young adults. Such statistics demonstrate the importance of interventions by family and friends, the importance of early diagnosis, and treatment by medical staff, in order to prevent suicide amongst youth at-risk. However, some data showed an opposite conclusion. Most depression symptoms are reported more frequently by females; such as sadness (reported by 85.1% of women and 54.3% of men) and crying (approximately 63.4% of women and 42.9% of men). Women have a higher probability to experience depression than men, with the prevalence of 19.2% and 13.5% respectively.
Risk factor
Risk factors for adolescent depression include a family history of depression, a personal history of trauma, family conflict, minority sexual orientation, or having a chronic medical illness. There tends to be higher prevalence rates and more severe symptoms in adolescent girls when compared to adolescent boys. These higher rates are also applicable in older adolescents when compared to younger adolescents. This may be due to hormonal fluctuations that may make adolescent women more vulnerable to depression. The fact that increased prevalence of depression correlates with hormonal changes in women, particularly during puberty, suggests that female hormones may be a trigger for depression. The gender gap in depression between adolescent men and women has been linked to young women's lower levels of positive thinking, need for approval, and self-focusing in negative conditions. Frequent exposure to victimization or bullying was related to high risks of depression, ideation and suicide attempts compared to those not involved in bullying. Nicotine dependence is also associated with depression, anxiety, and poor dieting, mostly in young men. Although causal direction has not been established, involvement in any sex or drug use is cause for concern. Children who develop major depression are more likely to have a family history of the disorder (often a parent who experienced depression at an early age) than patients with adolescent- or adult-onset depression. Adolescents with depression are also likely to have a family history of depression, though the correlation is not as high as it is for children.
Comorbidity
There is also a substantial comorbidity rate with depression in children with anxiety disorder, conduct disorder, and impaired social functioning. Particularly, there is a high comorbidity rate with anxiety, ranging from 15.9% to 75%. Conduct disorders also have a significant comorbidity with depression in children and adolescents, with a rate of 23% in one longitudinal study. Beyond other clinical disorders, there is also an association between depression in childhood, poor psychosocial and academic outcomes, as well as a higher risk for substance abuse and suicide.
The prevalence of psychiatric comorbidities during adolescence may vary by race and ethnicity.
Social causes
Adolescents are engaged in a search for identity and meaning in their lives. They have also been regarded as a unique group with a wide range of difficulties and problems in their transition to adulthood. Academic pressure, intrapersonal and interpersonal difficulties, death of loved ones, illnesses, and loss of relationships, have shown to be significant stressors in young people. While it is a normal part of development in adolescence to experience distressing and disabling emotions, there is an increasing incidence of mental illness globally. Depression is usually a response to life events such as relationship issues, financial problems, physical illness, bereavement, etc. Some people can become depressed for no obvious reason and their suffering is just as real as those reacting from life events. Psychological makeup can also play a role in vulnerability to depression. People who have low self-esteem, constantly view themselves and the world with pessimism, or are readily overwhelmed by stress, may be especially prone to depression. Community surveys find that women are more likely than men to say they are under stress. Other studies suggest that women are more likely than men to become depressed in response to a stressful event. Women are also more likely to experience certain kinds of severe stress such as child sexual abuse, adult sexual assaults, and domestic violence. Furthermore, depression can be the result of a bad experience, one of which might occur during athletics where social causes transcend into hierarchy practices in the form of bullying, which can root the initial cause.
Diagnosis
According to the DSM-IV, children must exhibit either a depressed mood or a loss of interest/pleasure in normal activities. These activities may include school, extracurricular activities, or peer interactions. Depressive moods in children can be expressed as being unusually irritable. These expressions may be displayed by "acting out," behaving recklessly, or reacting with anger/hostility. Children who do not have the cognitive or language development to properly express mood states can also exhibit their mood through physical complaints such as showing sad facial expressions (frowning) and poor eye contact. A child must also exhibit four other symptoms in order to be clinically diagnosed. However, according to the Omnigraphics Health References Series: Depression Sourcebook, Third Edition, a more calculated evaluation must be given by a medical or mental health professional such as a physiologist or psychiatrist. Following the bases of symptoms, signs include but are not limited to, an unusual change in sleep habits (for example, trouble sleeping or overly indulged sleeping hours); a significant amount of weight gain/loss by the lack or excessive eating; experiencing aches/pains for no apparent reason that can be found; and an inability to concentrate on tasks or activities. If these symptoms are present for a period of two weeks or longer, it is safe to make the assumption that the child, or anybody else for that matter, is falling into major depression.
Assessment
It is recommended by the American Academy of Pediatrics that primary care providers screen children and adolescents for depression with validated screening tools, self-rated, or clinician-administered ones, once per year. However, there is no universally recommended screening tool and the clinician is free to choose from various validated ones based on personal preference. Once the screening tool indicates the potential presence of a depression, a thorough diagnostic assessment is recommended. In early 2016, the USPSTF released an updated recommendation for the screening of adolescents ages 12 to 18 years for major depressive disorder (MDD). Appropriate treatment and follow-up should be provided for adolescents who screen positive.
Correlation between adolescent depression and adulthood obesity
According to research conducted by Laura P. Richardson et al., major depression occurred in 7% of the cohort during early adolescence (11, 13, and 15 years of age) and 27% during late adolescence (18 and 21 years of age). At 26 years of age, 12% of study members were obese. After adjusting for each individual's baseline body mass index (calculated as the weight in kilograms divided by the square of height in meters), depressed late-adolescent girls were at a greater than 2-fold increased risk for obesity in adulthood compared with their non-depressed female peers (relative risk, 2.32; 95% confidence interval, 1.29-3.83). A dose-response relationship between the number of episodes of depression during adolescence and the risk for adult obesity was also observed in female subjects. The association was not observed for late adolescent boys or for early adolescent boys or girls.
Correlation between child depression and adolescent cardiac risks
According to research by RM Carney et al., any history of child depression influences the occurrence of adolescent cardiac risk factors, even if individuals no longer suffer from depression. They are much more likely to develop heart disease as adults.
Distinction from major depressive disorder in adults
While there are many similarities to adult depression, especially in expression of symptoms, there are many differences that create a distinction between the two diagnoses. Research has shown that when a child's age is younger at diagnosis, typically there will be a more noticeable difference in the expression of symptoms from the classic signs in adult depression. One major difference between the symptoms exhibited in adults and in children is that children have higher rates of internalization; therefore, symptoms of child depression are more difficult to recognize. One major cause of this difference is that many of the neurobiological effects in the brain of adults with depression are not fully developed until adulthood. Therefore, in a neurological sense children and adolescents express depression differently.
Treatment
Psychotherapy and medications are commonly used treatment options. In some research, adolescents showed a preference for psychotherapy rather than antidepressant medication for treatment. For adolescents, cognitive behavioral therapy and interpersonal therapy have been empirically supported as effective treatment options. For children and adolescents with moderate-to-severe depressive disorder, fluoxetine seems to be best treatment (either with or without cognitive behavioural therapy) but more research is needed to be certain.
Clinicians often divide treatment into three phases: In the acute phase, which usually lasts six to 12 weeks, the goal is to relieve symptoms. In the continuation phase, which can last for several more months, the goal is to maximize improvements. At this stage, clinicians may make adjustments to the dose of a medication. In the maintenance phase, the aim is to prevent relapse. Sometimes the dose of a drug is lowered at this stage, or psychotherapy carries more of the weight. Unique differences in life experience, temperament, and biology make treatment a complex matter; no single treatment is right for everyone.
Pediatric massage therapy may have an immediate effect on a child's emotional state at the time of the massage, but sustained effects on depression have not been identified.
Treatment programs have been developed that help reduce the symptoms of depression. These treatments focus on immediate symptom reduction by concentrating on teaching children skills pertaining to primary and secondary control. While much research is still needed to confirm this treatment program's efficacy, one study showed it to be effective in children with mild or moderate depressive symptoms.
Identification and treatment of concomitant parental depression is associated with improved responses to treatment in adolescents with depression as having a parent with depression may negatively affect a young person's response to therapy as well as their outlook on depression.
Talk therapy
There are a variety of common types of talk therapy. These can assist people to live more fully, help improve good feelings, and have a better life. Effective psychotherapy for children always includes parent involvement, teaching skills that are practiced at home or at school, and measures of progress that are tracked over time. In many types, men are encouraged to open up more emotionally and communicate their personal distress, while women are encouraged to be assertive of their own strengths. Often psychotherapy teaches coping skills while allowing the teens or children to explore feelings and events in a safe environment.
Severe depression, low global functioning, higher scores on suicidality scales, co-existing anxiety, distorted thought processes and feelings of hopelessness are characteristics of adolescent depression that are associated with a poor response to psychotherapy. If there is concomitant family conflict then interpersonal therapy is more effective than cognitive therapy.
Cognitive therapy
Cognitive therapy aims to change harmful ways of thinking and reframe negative thoughts in a more positive way. Aims of cognitive therapy include various steps of patient learning. During cognitive behavioral therapy, children and adolescents with depression work with therapists to learn about their diagnosis, how to identify and reshape negative thought patterns, and how to increase engagement in enjoyable activities. CBT-trained therapists work with individuals, families, and groups. The approach can be used to help anyone irrespective of ability, culture, race, gender, or sexual preference. It can be applied with or without concurrent psychopharmacological medication, depending on the severity or nature of each patient's problem. The duration of cognitive-behavioral therapy varies, although it typically is thought of as one of the briefer psychotherapeutic treatments. Especially in research settings, duration of CBT is usually short, between 10 and 20 sessions. In routine clinical practice, duration varies depending on patient comorbidity, defined treatment goals, and the specific conditions of the health care system.
Behavioral therapy
Behavioral therapy helps change harmful ways of acting and gain control over behavior which is causing problems.
Interpersonal therapy
Interpersonal therapy helps one learn to relate better with others, express feelings, and develop better social skills. Interpersonal therapy helps the patient identify and cope through reoccurring conflicts within their relationships. Typically, the therapy will focus on one of the four specific problems, grief, social isolation, conflicts about roles and social expectations, or the effect of a major life change.
Family therapy
The principles of group dynamics are relevant to family therapists who must not only work with individuals, but with entire family systems. Family counseling can help families understand how a child's individual challenges may affect relations with parents and siblings and vice versa.
Therapists strive to understand not just what the group members say, but how these ideas are communicated (process). Therapists can help families improve the way they relate and thus enhance their own capacity to deal with the content of their problems by focusing on the process of their discussions. Virginia Satir expanded on the concept of how individuals behave and communicate in groups by describing several family roles that can serve to stabilize expected characteristic behavior patterns in a family. For instance, if one child is considered to be a "rebel child", a sibling may take on the role of the "good child" to alleviate some of the stress in the family. This concept of role reciprocity is helpful in understanding family dynamics because the complementary nature of roles makes behaviors more resistant to change.
Antidepressants
Main article: AntidepressantClinicians usually recommend a selective serotonin reuptake inhibitor (SSRI) as a first line pharmacologic treatment for depression in adolescence. For children and adolescents with moderate-to-severe depressive disorder, fluoxetine seems to be the best treatment (either with or without cognitive behavioural therapy) but more research is needed to be certain. Sertraline, escitalopram, duloxetine might also help in reducing symptoms. Escitalopram and fluoxetine are among the safest antidepressants to give to children and adolescents. The combination of psychotherapy with medications has been shown to be more effective for the treatment of depression in adolescence than medications alone.
SSRIs act on the serotonin system that affects mood, arousal, anxiety, impulses, and aggression. SSRIs also appear to indirectly influence other neurotransmitter systems, including those involving norepinephrine and dopamine. Some possible adverse reactions of SSRIs include headache, gastrointestinal side effects, dry mouth, sedation or insomnia and activation. Activation refers to a state of psychomotor agitation that includes symptoms of insomnia, disinhibition and restlessness that may result in discontinuation of a medication. There is a rare risk of suicidal thoughts or behaviors with SSRIs especially when treatment is started or the dose is increased, with the rate being up to 0.7% as compared to placebo in early meta analyses of SSRIs in the treatment of adolescent depression. This led the FDA to issue a black box warning regarding this risk. Once remission is achieved, the medications are continued for at least 6 to 12 months and then there is consideration of discontinuing them. Early or premature discontinuation of medications, prior to 6 to 12 months of having achieved remission, is associated with an increased risk of relapse of the depression.
Other medications can be added to SSRIs if a partial response is achieved and further improvement is needed; these agents include lithium, bupropion and atypical antipsychotics. These options are medications that work in different ways. Bupropion (Wellbutrin) works through the neurotransmitters norepinephrine and dopamine, while mirtazapine (Remeron) affects transmission of norepinephrine and serotonin. The drugs venlafaxine (Effexor) and duloxetine (Cymbalta) work in part by simultaneously inhibiting the reuptake of serotonin and norepinephrine. The oldest drugs on the market are not prescribed often, but may be a good option for some women. These include tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). TCAs may cause side effects like dry mouth, constipation, or dizziness. MAOIs can cause sedation, insomnia, dizziness, and weight gain. To avoid the risk of a rapid rise in blood pressure, people taking MAOIs must also avoid eating a substance called tyramine, found in yogurt, aged cheese, pickles, beer, and red wine. Some drug side effects subside with time, while others may lessen when a drug dose is lowered.
In the USA, as of 2021, the FDA has approved the SSRIs fluoxetine and escitalopram for the treatment of depression in adolescents but other SSRIS or serotonin norepinephrine reuptake inhibitors (SNRIs) are often used off label for treatment.
Research
Differences in the brain's structure and function appear to be present in adolescents with depression though this may depend on age. Younger adolescents, mostly under the age of 18, with depression have shown greater white matter volume within frontal regions of the brain, greater cortical thickness in the anterior cingulate cortex and medial orbitofrontal cortex, as well as greater functional connectivity between cortico-limbic brain regions. Whereas older adolescents, mostly above the age of 18, appear to show lower cortical surface area in regions including the lingual, occipital gyri, as well as medial orbitofrontal and motor cortices. Results such as these have led to the hypothesis that the biological causes of depression may in part be neurodevelopmental, with its biological underpinnings forming early on in brain development.
History
Although antidepressants were used by child and adolescent psychiatrists to treat major depressive disorder, they were not always used in young people with a comorbid conduct disorder because of the risks of overdose in such a population. Tricyclic antidepressant were the predominant antidepressants used at that time in this population. With the advent of selective serotonin re-uptake inhibitors (SSRIs), child and adolescent psychiatrists began prescribing more anti-depressants in the comorbid conduct disorder/major depressive group because of there was, and is, not a significant correlation of adverse response at higher doses. This raises the possibility that more effective treatment of these young people might also improve their outcomes in adult life. Although treatment rates are becoming more stable, there is a trend that suggests that little progress has been made in narrowing the mental health treatment gap for adolescent depression. The FDA has also placed a black box warning on using antidepressants, leading doctors to be hesitant on prescribing them to adolescents.
Controversies
Throughout the development and research of this disorder, controversies have emerged over the legitimacy of depression in childhood and adolescence as a diagnosis, the proper measurement and validity of scales to diagnose, and the safety of particular treatments.
Legitimacy as a diagnosis
In early research of depression in children, there was debate as to whether or not children could clinically fit the criteria for major depressive disorder. However, since the 1970s, it has been accepted among the psychological community that depression in children can be clinically significant. The more pertinent controversy in psychology today centers around the clinical significance of sub-threshold mood disorders. This controversy stems from the debate regarding the definition of the specific criteria for a clinically significant depressed mood in relation to the cognitive and behavioral symptoms. Some psychologists argue that the effects of mood disorders in children and adolescents, or rather the few that exist but do not fully meet the criteria for depression, do not have severe enough risks. Children in this area of severity, they argue, should receive some sort of treatment since the effects could still be severe. However, since there has yet to be enough research or scientific evidence to support that children that fall within the area just shy of a clinical diagnosis require treatment, other psychologists are hesitant to support the dispensation of treatment.
Diagnosis controversy
In order to diagnose a child with depression, different screening measures and reports have been developed to help clinicians make a proper decision. However, the accuracy and effectiveness of certain measures that help psychologists diagnose children have come into question. Due to absence of strong evidence that screening children and adolescents for depression leads to improved mental health outcomes, it has been questioned whether it causes more harm than benefit. Questions have also surfaced about the safety and effectiveness of antidepressant medications.
Measurement reliability
The effectiveness of dimensional child self-report checklists has been criticized. Although literature has documented strong psychometric properties, other studies have shown a poor specificity at the top end of scales, resulting in most children with high scores not meeting the diagnostic criteria for depression. Another issue with reliability of measurement for diagnosis occurs in parent, teacher, and child reports. One study, which observed the similarities between child self-report and parent reports on the child's symptoms of depression, acknowledged that on more subjective symptom reports measures, the agreement was not significant enough to be considered reliable. Two self-report scales demonstrated an erroneous classification of 25% of children in both the depressed and controlled samples. A large concern in the use of self-report scales is the accuracy of the information collected. The main controversy is caused by uncertainty about how the data from these multiple informants can or should be combined to determine whether a child can be diagnosed with depression.
Treatment issues
The controversy over the use of antidepressants began in 2003 when Great Britain's Department of Health stated that, based on data collected by the Medicines and Healthcare products Regulatory Agency, paroxetine (an antidepressant) should not be used on patients under the age of 18. Since then, the United States Food and Drug Administration (FDA) has issued a warning describing the increased risk of adverse effects of antidepressants used as treatment in those under the age of 18. The main concern is whether the risks outweigh the benefits of the treatment. In order to decide this, studies often look at the adverse effects caused by the medication in comparison to the overall symptom improvement. While multiple studies have shown an improvement or efficacy rate of over 50%, the concern of severe side effects – such as suicidal ideation or suicidal attempts, worsening of symptoms, or increase in hostility – are still concerns when using antidepressants. However, an analysis of multiple studies argues that while the risk of suicidal ideation or attempt is present, the benefits significantly outweigh the risks. Due to the variability of these studies, it is currently recommended that if antidepressants are chosen as a method of treatment for children or adolescents, the clinician monitor closely for adverse symptoms, since there is still no definitive answer on why they are depressed.
In the UK, National Institute for Health and Care Excellence (NICE) guidelines state that antidepressants for children and adolescents with depression should be prescribed together with therapy and after being assessed by a child and adolescent psychiatrist. However, between 2006 and 2017, only 1 in 4 of 12-17 year olds who were prescribed an SSRI by their GP had seen a specialist psychiatrist and 1 in 6 has seen a paediatrician. Half of these prescriptions were for depression. Among the suggested possible reasons why GPs are not following the guidelines are the difficulties of accessing talking therapies, long waiting lists and the urgency of treatment. According to some researchers, strict adherence to treatment guidelines would limit access to effective medication for young people with mental health problems.
See also
References
- ^ Birmaher B, Ryan ND, Williamson DE, Brent DA, Kaufman J, Dahl RE, et al. (November 1996). "Childhood and adolescent depression: a review of the past 10 years. Part I". Journal of the American Academy of Child and Adolescent Psychiatry. 35 (11): 1427–1439. doi:10.1097/00004583-199611000-00011. PMID 8936909. S2CID 11623499.
- "What Causes Mental Illness in Youth?". 23 March 2022.
- "What Causes Mental Illness in Adolescence". 15 November 2018.
- American Academy of Child & Adolescent Psychiatry. The Depressed Child, "Facts for Families," No. 4 (5/08)
- "About the Cochrane Database of Systematic Reviews | Cochrane Library". www.cochranelibrary.com. Retrieved 2023-09-21.
- Hetrick SE, Cox GR, Witt KG, Bir JJ, Merry SN (August 2016). "Cognitive behavioural therapy (CBT), third-wave CBT and interpersonal therapy (IPT) based interventions for preventing depression in children and adolescents". The Cochrane Database of Systematic Reviews. 2016 (8): CD003380. doi:10.1002/14651858.CD003380.pub4. PMC 8407360. PMID 27501438.
- Eapen V, Črnčec R (January 2012). "Strategies and challenges in the management of adolescent depression". Current Opinion in Psychiatry. 25 (1): 7–13. doi:10.1097/yco.0b013e32834de3bd. PMID 22156932. S2CID 6721532.
- The Association for University and College ... - AUCCCD. www.aucccd.org/assets/documents/aucccd 2016 monograph - public.pdf.
- ^ Kovacs M, Feinberg TL, Crouse-Novak MA, Paulauskas SL, Finkelstein R (March 1984). "Depressive disorders in childhood. I. A longitudinal prospective study of characteristics and recovery". Archives of General Psychiatry. 41 (3): 229–237. doi:10.1001/archpsyc.1984.01790140019002. PMID 6367688.
- Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein RE (March 2018). "Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management". Pediatrics. 141 (3). doi:10.1542/peds.2017-4082. PMID 29483201.
- ^ Kessler RC, Avenevoli S, Ries Merikangas K (June 2001). "Mood disorders in children and adolescents: an epidemiologic perspective". Biological Psychiatry. 49 (12): 1002–1014. doi:10.1016/s0006-3223(01)01129-5. PMID 11430842. S2CID 10397930.
- Hankin BL, Abramson LY, Moffitt TE, Silva PA, McGee R, Angell KE (February 1998). "Development of depression from preadolescence to young adulthood: emerging gender differences in a 10-year longitudinal study". Journal of Abnormal Psychology. 107 (1): 128–140. doi:10.1037/0021-843x.107.1.128. PMID 9505045. S2CID 29783051.
- Nolen-Hoeksema S, Girgus JS (May 1994). "The emergence of gender differences in depression during adolescence". Psychological Bulletin. 115 (3): 424–443. doi:10.1037/0033-2909.115.3.424. PMID 8016286.
- Maughan B, Collishaw S, Stringaris A (February 2013). "Depression in childhood and adolescence". Journal of the Canadian Academy of Child and Adolescent Psychiatry. 22 (1): 35–40. PMC 3565713. PMID 23390431.
- Shaffer D, Gould MS, Fisher P, Trautman P, Moreau D, Kleinman M, Flory M (April 1996). "Psychiatric diagnosis in child and adolescent suicide". Archives of General Psychiatry. 53 (4): 339–348. doi:10.1001/archpsyc.1996.01830040075012. PMID 8634012.
- "Mental health of adolescents". www.who.int. Retrieved 2023-06-07.
- Shaffer D, Craft L (1999). "Methods of adolescent suicide prevention". The Journal of Clinical Psychiatry. 60 (Suppl 2): 70–4, discussion 75–6, 113–6. PMID 10073391.
- Weissman MM, Wolk S, Goldstein RB, Moreau D, Adams P, Greenwald S, et al. (May 1999). "Depressed adolescents grown up". JAMA. 281 (18): 1707–1713. doi:10.1001/jama.281.18.1707. PMID 10328070. S2CID 46242201.
- Lopez Molina MA, Jansen K, Drews C, Pinheiro R, Silva R, Souza L (7 May 2013). "Major depressive disorder symptoms in male and female young adults". Psychology, Health & Medicine. 19 (2): 136–145. doi:10.1080/13548506.2013.793369. PMID 23651450. S2CID 32876100.
- ^ Miller L, Campo JV (July 2021). "Depression in Adolescents". The New England Journal of Medicine. 385 (5): 445–449. doi:10.1056/NEJMra2033475. PMID 34320289. S2CID 236498366.
- ^ "Women and depression". Harvard Health. Retrieved 2020-06-13.
- Albert PR (July 2015). "Why is depression more prevalent in women?". Journal of Psychiatry & Neuroscience. 40 (4): 219–221. doi:10.1503/jpn.150205. PMC 4478054. PMID 26107348.
- Calvete E, Cardeñoso O (April 2005). "Gender differences in cognitive vulnerability to depression and behavior problems in adolescents". Journal of Abnormal Child Psychology. 33 (2): 179–192. doi:10.1007/s10802-005-1826-y. PMID 15839496. S2CID 36986016.
- Brunstein Klomek A, Marrocco F, Kleinman M, Schonfeld IS, Gould MS (January 2007). "Bullying, depression, and suicidality in adolescents". Journal of the American Academy of Child and Adolescent Psychiatry. 46 (1): 40–49. doi:10.1097/01.chi.0000242237.84925.18. PMID 17195728.
- Psujek JK, Martz DM, Curtin L, Michael KD, Aeschleman SR (February 2004). "Gender differences in the association among nicotine dependence, body image, depression, and anxiety within a college population". Addictive Behaviors. 29 (2): 375–380. doi:10.1016/j.addbeh.2003.08.031. PMID 14732426.
- Hallfors DD, Waller MW, Ford CA, Halpern CT, Brodish PH, Iritani B (October 2004). "Adolescent depression and suicide risk: association with sex and drug behavior". American Journal of Preventive Medicine. 27 (3): 224–231. doi:10.1016/s0749-3797(04)00124-2. PMID 15450635.
- "A Fact Sheet". National Institute of Mental Health.
- "Why do Women Get Depressed More Than Men?". 2012-09-22.
- ^ Angold A, Costello EJ (December 1993). "Depressive comorbidity in children and adolescents: empirical, theoretical, and methodological issues". The American Journal of Psychiatry. 150 (12): 1779–1791. CiteSeerX 10.1.1.475.1415. doi:10.1176/ajp.150.12.1779. PMID 8238631.
- Brady EU, Kendall PC (March 1992). "Comorbidity of anxiety and depression in children and adolescents". Psychological Bulletin. 111 (2): 244–255. doi:10.1037/0033-2909.111.2.244. PMID 1557475. S2CID 17341178.
- Kovacs M, Paulauskas S, Gatsonis C, Richards C (1988). "Depressive disorders in childhood. III. A longitudinal study of comorbidity with and risk for conduct disorders". Journal of Affective Disorders. 15 (3): 205–217. doi:10.1016/0165-0327(88)90018-3. PMID 2975293.
- Weller BE, Blanford KL, Butler AM (June 2018). "Estimated Prevalence of Psychiatric Comorbidities in U.S. Adolescents With Depression by Race/Ethnicity, 2011-2012". The Journal of Adolescent Health. 62 (6): 716–721. doi:10.1016/j.jadohealth.2017.12.020. PMID 29784115. S2CID 29157841.
- ^ Ahmed, Z., & Julius, S. H. (2015). The relationship between depression, anxiety and stress among women college students. Indian Journal of Health and Wellbeing, 6(12), 1232-1234. ProQuest 1776182512
- Brown, E. (2021)
- Sutton A, ed. (2012). "Depression in Children and Adolescents". Depression Sourcebook, 3rd Edition. Detroit: Omnigraphics: Health Reference Series. pp. 131–143.
- Zuckerbrot RA, Cheung A, Jensen PS, Stein RE, Laraque D (March 2018). "Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management". Pediatrics. 141 (3). doi:10.1542/peds.2017-4081. PMID 29483200.
- "Final Update Summary: Depression in Children and Adolescents: Screening - US Preventive Services Task Force". www.uspreventiveservicestaskforce.org. Retrieved 2016-03-30.
- Richardson LP, Davis R, Poulton R, McCauley E, Moffitt TE, Caspi A, Connell F (August 2003). "A longitudinal evaluation of adolescent depression and adult obesity". Archives of Pediatrics & Adolescent Medicine. 157 (8): 739–745. doi:10.1001/archpedi.157.8.739. PMID 12912778.
- Carney RM, et al. (15 May 2013). "Depression in kids linked to cardiac risks in teens". Science Daily. Retrieved 4 July 2014.
- Kaufman J, Martin A, King RA, Charney D (June 2001). "Are child-, adolescent-, and adult-onset depression one and the same disorder?". Biological Psychiatry. 49 (12): 980–1001. doi:10.1016/s0006-3223(01)01127-1. PMID 11430841. S2CID 24024851.
- Zahn-Waxler C, Klimes-Dougan B, Slattery MJ (2000). "Internalizing problems of childhood and adolescence: prospects, pitfalls, and progress in understanding the development of anxiety and depression". Development and Psychopathology. 12 (3): 443–466. doi:10.1017/s0954579400003102. PMID 11014747. S2CID 25880656.
- Bradley KL, McGrath PJ, Brannen CL, Bagnell AL (June 2010). "Adolescents' attitudes and opinions about depression treatment". Community Mental Health Journal. 46 (3): 242–251. doi:10.1007/s10597-009-9224-5. PMID 19636707. S2CID 40090855.
- ^ "Prozac may be the best treatment for young people with depression – but more research is needed". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2020-10-12. doi:10.3310/alert_41917. S2CID 242952585.
- ^ Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, et al. (July 2020). "Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis". The Lancet. Psychiatry. 7 (7): 581–601. doi:10.1016/S2215-0366(20)30137-1. PMC 7303954. PMID 32563306.
- Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ (October 2006). "Effectiveness of complementary and self-help treatments for depression in children and adolescents". The Medical Journal of Australia. 185 (7): 368–372. doi:10.5694/j.1326-5377.2006.tb00612.x. PMID 17014404. S2CID 11020944.
- Weisz JR, Thurber CA, Sweeney L, Proffitt VD, LeGagnoux GL (August 1997). "Brief treatment of mild-to-moderate child depression using primary and secondary control enhancement training". Journal of Consulting and Clinical Psychology. 65 (4): 703–707. doi:10.1037/0022-006x.65.4.703. PMID 9256573. S2CID 18088943.
- "An overview of talk therapy". Archived from the original on 2013-02-18. Retrieved 2012-07-25.
- ^ "Children and Mental Health". NIMH. Retrieved 2019-11-20.
- Danielsson UE, Bengs C, Samuelsson E, Johansson EE (May 2011). ""My greatest dream is to be normal": the impact of gender on the depression narratives of young Swedish men and women". Qualitative Health Research. 21 (5): 612–624. doi:10.1177/1049732310391272. PMID 21149850. S2CID 23112329.
- "Depression | Mental Health America".
- Oar EL, Johnco C, Ollendick TH (December 2017). "Cognitive Behavioral Therapy for Anxiety and Depression in Children and Adolescents". The Psychiatric Clinics of North America. 40 (4): 661–674. doi:10.1016/j.psc.2017.08.002. PMID 29080592.
- Leichsenring, F., Hiller, W., Weissberg, M., & Leibing, E. (2006). Cognitive-behavioral therapy and psychodynamic psychotherapy: Techniques, efficacy, and indications. American Journal of Psychotherapy, 60(3), 233-59. doi:10.1176/appi.psychotherapy.2006.60.3.233
- Nichols & Schwartz, Family Therapy: Concepts and Methods. Fourth Edition. Allyn & Bacon 1998
- "Family therapy historical overview". Archived from the original on 2007-06-07. Retrieved 2012-07-25.
- ^ Hetrick SE, McKenzie JE, Bailey AP, Sharma V, Moller CI, Badcock PB, et al. (May 2021). Cochrane Common Mental Disorders Group (ed.). "New generation antidepressants for depression in children and adolescents: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2021 (5): CD013674. doi:10.1002/14651858.CD013674.pub2. PMC 8143444. PMID 34029378.
- Boaden K, Tomlinson A, Cortese S, Cipriani A (2020-09-02). "Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment". Frontiers in Psychiatry. 11: 717. doi:10.3389/fpsyt.2020.00717. PMC 7493620. PMID 32982805.
- "Psychiatric drugs given to children and adolescents have been ranked in order of safety". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2020-09-01. doi:10.3310/alert_40795. S2CID 241309451.
- Solmi, Marco; Fornaro, Michele; Ostinelli, Edoardo G.; Zangani, Caroline; Croatto, Giovanni; Monaco, Francesco; Krinitski, Damir; Fusar-Poli, Paolo; Correll, Christoph U. (11 May 2020). "Safety of 80 antidepressants, antipsychotics, anti-attention-deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: a large scale systematic meta-review of 78 adverse effects". World Psychiatry. 19 (2): 214–232. doi:10.1002/wps.20765. ISSN 1723-8617. PMC 7215080. PMID 32394557.
- Villa LM, Goodyer IM, Tait R, Kelvin R, Reynolds S, Wilkinson PO, Suckling J (May 2020). "Cognitive behavioral therapy may have a rehabilitative, not normalizing, effect on functional connectivity in adolescent depression" (PDF). Journal of Affective Disorders. 268: 1–11. doi:10.1016/j.jad.2020.01.103. PMID 32157998. S2CID 212665652.
- Reynolds S, Carrey N, Jaworska N, Langevin LM, Yang XR, Macmaster FP (March 2014). "Cortical thickness in youth with major depressive disorder". BMC Psychiatry. 14 (1): 83. doi:10.1186/1471-244x-14-83. PMC 3994552. PMID 24645731.
- Schmaal L, Hibar DP, Sämann PG, Hall GB, Baune BT, Jahanshad N, et al. (June 2017). "Cortical abnormalities in adults and adolescents with major depression based on brain scans from 20 cohorts worldwide in the ENIGMA Major Depressive Disorder Working Group". Molecular Psychiatry. 22 (6): 900–909. doi:10.1038/mp.2016.60. PMC 5444023. PMID 27137745.
- Casey BJ, Jones RM, Levita L, Libby V, Pattwell SS, Ruberry EJ, et al. (April 2010). "The storm and stress of adolescence: insights from human imaging and mouse genetics". Developmental Psychobiology. 52 (3): 225–235. doi:10.1002/dev.20447. PMC 2850961. PMID 20222060.
- Whittle S, Lichter R, Dennison M, Vijayakumar N, Schwartz O, Byrne ML, et al. (May 2014). "Structural brain development and depression onset during adolescence: a prospective longitudinal study". The American Journal of Psychiatry. 171 (5): 564–571. doi:10.1176/appi.ajp.2013.13070920. PMID 24577365.
- Dwyer, Jennifer B.; Bloch, Michael H. (September 2019). "Antidepressants for Pediatric Patients". Current Psychiatry. 18 (9): 26–42F. ISSN 1537-8276. PMC 6738970. PMID 31511767.
- Hynes J, McCune N (August 2002). "Follow-up of childhood depression: historical factors". The British Journal of Psychiatry. 181 (2): 166–7, author reply 167. doi:10.1192/bjp.181.2.166. PMID 12151295.
- ^ Mojtabai R, Olfson M, Han B (December 2016). "National Trends in the Prevalence and Treatment of Depression in Adolescents and Young Adults". Pediatrics. 138 (6): e20161878. doi:10.1542/peds.2016-1878. PMC 5127071. PMID 27940701.
- ^ Chambers WJ, Puig-Antich J, Tabrizi MA, Davies M (August 1982). "Psychotic symptoms in prepubertal major depressive disorder". Archives of General Psychiatry. 39 (8): 921–927. doi:10.1001/archpsyc.1982.04290080037006. PMID 7103681.
- ^ Barrett ML, Berney TP, Bhate S, Famuyiwa OO, Fundudis T, Kolvin I, Tyrer S (July 1991). "Diagnosing childhood depression who should be interviewed--parent or child? The Newcastle Child Depression Project". The British Journal of Psychiatry. Supplement. 159 (11): 22–27. doi:10.1192/S0007125000292118. PMID 1840754. S2CID 13631546.
- Roseman M, Kloda LA, Saadat N, Riehm KE, Ickowicz A, Baltzer F, et al. (December 2016). "Accuracy of Depression Screening Tools to Detect Major Depression in Children and Adolescents: A Systematic Review". Canadian Journal of Psychiatry. 61 (12): 746–757. doi:10.1177/0706743716651833. PMC 5564894. PMID 27310247.
- ^ Cheung AH, Emslie GJ, Mayes TL (July 2005). "Review of the efficacy and safety of antidepressants in youth depression". Journal of Child Psychology and Psychiatry, and Allied Disciplines. 46 (7): 735–754. doi:10.1111/j.1469-7610.2005.01467.x. PMID 15972068.
- Fundudis T, Berney TP, Kolvin I, Famuyiwa OO, Barrett L, Bhate S, Tyrer SP (July 1991). "Reliability and validity of two self-rating scales in the assessment of childhood depression". The British Journal of Psychiatry. Supplement. 159 (11): 36–40. doi:10.1192/S0007125000292131. PMID 1840756. S2CID 22414342.
- Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. (April 2007). "Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials". JAMA. 297 (15): 1683–1696. doi:10.1001/jama.297.15.1683. PMID 17440145.
- ^ "Antidepressants for children and teenagers: what works for anxiety and depression?". NIHR Evidence (Plain English summary). National Institute for Health and Care Research. 2022-11-03. doi:10.3310/nihrevidence_53342. S2CID 253347210.
- Jack RH, Joseph RM, Coupland C, Butler D, Hollis C, Morriss R, et al. (April 2020). "Secondary care specialist visits made by children and young people prescribed antidepressants in primary care: a descriptive study using the QResearch database". BMC Medicine. 18 (1): 93. doi:10.1186/s12916-020-01560-7. PMC 7191694. PMID 32349753.
- "GPs giving antidepressants to children against guidelines". The Guardian. 2022-11-04. Retrieved 2022-11-05.
- Walkup JT, Strawn JR (May 2020). "High-quality antidepressant prescribing: please consider whether "perfection is the enemy of progress"". BMC Medicine. 18 (1): 150. doi:10.1186/s12916-020-01621-x. PMC 7243321. PMID 32438910.
External links
- Depression in Children on WebMD.
- Antidepressants for children and teenagers: what works for anxiety and depression? – plain English summary of research by the NIHR.